Pharma group Opiant Pharmaceuticals (OTCQB:LLTP) is to convene its medical advisory board to discuss its development programmes in substance use, addictive and eating disorders, it told investors.
“The medical advisory board meeting is an important step in the process of moving our clinical programs forward,” said Roger Crystal, managing director and chief executive of Opiant.
“We are delighted to have the engagement of world leaders in their respective fields, and we look forward to their input."
More than 45 million people have one of the disorders above.
The firm has what's called opioid antagonist nasal delivery technology and says it's positioned to become a leader in these treatment markets.
Its first product, NARCAN Nasal Spray, is approved for marketing in the USA by the company’s partner, Adapt Pharma.
Currently, Opiant is developing opioid antagonists for the treatment of substance use, addictive and eating disorders, with a near term focus on cocaine use disorder and binge eating disorder (BED).